T1	p 6 46	Recurrent epithelial ovarian carcinoma :
T2	p 233 280	patients with epithelial ovarian carcinoma that
T3	p 307 314	respond
T4	p 318 360	first-line , platinum-based chemotherapy .
T5	p 382 434	Patients with measurable and assessable disease were
T6	p 587 625	Patients were stratified prospectively
T7	p 692 701	disease .
T8	p 712 738	total of 474 patients were
T9	p 1120 1147	platinum-sensitive patients
T10	p 1401 1407	median
T11	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T12	i 176 229	pegylated liposomal doxorubicin ( PLD ) and topotecan
T13	i 346 360	chemotherapy .
T14	i 457 475	either PLD 50 mg/m
T15	i 487 538	1-hour infusion every 4 weeks or topotecan 1.5 mg/m
T16	i 749 776	239 PLD and 235 topotecan )
T17	i 950 967	PLD and topotecan
T18	i 1068 1071	PLD
T19	i 1076 1080	56.7
T20	i 1091 1100	topotecan
T21	i 1202 1205	PLD
T22	i 1275 1278	PLD
T23	i 1286 1290	23.3
T24	i 1301 1310	topotecan
T25	i 1370 1379	topotecan
T26	i 1545 1554	topotecan
T27	i 1618 1627	topotecan
T28	i 1695 1708	growth factor
T29	i 1846 1849	PLD
T30	o 153 172	efficacy and safety
T31	o 831 870	overall progression-free survival rates
T32	o 923 949	overall response rates for
T33	o 1020 1049	Median overall survival times
T34	o 1210 1235	progression-free survival
T35	o 1317 1339	overall survival , PLD
T36	o 1489 1526	nonstatistically significant survival
T37	o 1569 1596	Severe hematologic toxicity
T38	o 1695 1737	growth factor or blood product utilization
T39	o 1766 1801	efficacy , favorable safety profile